Current controversies in early-stage melanoma : Questions on management and surveillance - 13/12/18
Abstract |
There are a number of controversies and uncertainties relating to the management and surveillance of patients with early-stage, localized (ie, stage 0, I, and II) cutaneous melanoma. While tumor stage is a critical predictor of clinical outcome and guides treatment, accurate determination of stage may be affected by the biopsy technique used and the method of sectioning before histologic review. A new molecular prognostic test is available but has not been formally incorporated into staging or treatment guidelines. There are no randomized controlled clinical trials to support guidelines for surveillance following the treatment of early-stage melanoma. In the second article in this continuing medical education series, we review the controversies and uncertainties relating to these issues. The questions we address are controversial because they speak to clinical scenarios for which there are no evidence-based guidelines or randomized clinical trials with the consequence of considerable variability in clinical practice. Our goal is to provide the clinician with up-to-date contextual knowledge to appreciate the multiple sides of each controversy and to suggest pathways to resolution.
Le texte complet de cet article est disponible en PDF.Key words : imaging, melanoma, staging, surveillance, transection
Abbreviations used : AJCC, CT, CXR, GEP, LM, MIS, NCCN, PET, SLNB, WLE
Plan
Supported by the University of Utah Department of Dermatology and the Huntsman Cancer Foundation (Dr Grossman). |
|
Conflicts of interest: None disclosed. |
|
Date of release: January 2019 |
|
Expiration date: January 2022 |
Vol 80 - N° 1
P. 15-25 - janvier 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?